Zhang Wei, Yu Yingyan
Department of Surgery, School of Medicine, The Ninth People's Hospital of Shanghai Jiao Tong University, Shanghai 200011, China.
Int J Mol Sci. 2011;12(9):5672-83. doi: 10.3390/ijms12095672. Epub 2011 Sep 5.
Abnormalities of chromosome 17 are important molecular genetic events in human breast cancers. Several famous oncogenes (HER2, TOP2A and TAU), tumor suppressor genes (p53, BRCA1 and HIC-1) or DNA double-strand break repair gene (RDM1) are located on chromosome 17. We searched the literature on HER2, TOP2A, TAU, RDM1, p53, BRCA1 and HIC-1 on the Pubmed database. The association of genes with chromosome 17, biological functions and potential significance are reviewed. In breast cancer, the polysomy 17 (three or more) is the predominant numerical aberration. HER2 amplification is widely utilized as molecular markers for trastuzumab target treatment. Amplified TOP2A, TAU and RDM1 genes are related to a significant response to anthracycline-based chemotherapy, taxane or cisplatin, respectively. In contrast, p53, BRCA1 and HIC-1 are important tumor suppressor genes related to breast carcinogenesis. This review focused on several crucial molecular markers residing on chromosome 17. The authors consider the somatic aberrations of chromosome 17 and associated genes in breast cancer.
17号染色体异常是人类乳腺癌重要的分子遗传学事件。几个著名的癌基因（HER2、TOP2A和TAU）、肿瘤抑制基因（p53、BRCA1和HIC-1）或DNA双链断裂修复基因（RDM1）都位于17号染色体上。我们在PubMed数据库中检索了关于HER2、TOP2A、TAU、RDM1、p53、BRCA1和HIC-1的文献。对这些基因与17号染色体的关联、生物学功能及潜在意义进行综述。在乳腺癌中，17号染色体多体性（三条或更多）是主要的数目畸变。HER2扩增被广泛用作曲妥珠单抗靶向治疗的分子标志物。TOP2A、TAU和RDM1基因扩增分别与对蒽环类化疗药物、紫杉烷或顺铂的显著反应相关。相反，p53、BRCA1和HIC-1是与乳腺癌发生相关的重要肿瘤抑制基因。本综述聚焦于位于17号染色体上的几个关键分子标志物。作者探讨了乳腺癌中17号染色体的体细胞畸变及相关基因。
